Novo mesto, 10 April 2012 - Krka, d.d., Novo mesto (“Krka”, the “Company”) announced today that it has received all necessary decisions from the Warsaw Stock Exchange (the “WSE”) and the National Depositary of Securities in Poland required for the commencement of trading on the WSE of all its ordinary shares. In connection with the admission and introduction of its shares to trading on the WSE, Krka has prepared and announced an Information Memorandum which is available on its website http://www.krka.biz/en/. The first listing of its shares on the WSE will take place on 11 April 2012.
Shares in Krka will continue to be listed on the Ljubljana Stock Exchange. The aim of the dual listing in Warsaw is to introduce a second, widely recognised listing platform to support the trading of Krka’s shares, and to attract more interest from international and Polish investors.
Krka’s President and Chief Executive, Mr. Jože Colarič, commented “As one of the leading global generic pharmaceutical companies, we are delighted to take this strategically important step of listing on the WSE. Although trading liquidity may take time to build up, we believe a listing on WSE will broaden our shareholder base and enhance Krka's capital markets flexibility going forward”. The Company owns 2,080,134 treasury shares (almost 5.9% of its existing share capital) which may be used to support liquidity in its trading on the WSE.
Dom Maklerski Banku Handlowego S.A., a Polish subsidiary of Citi, is acting as listing agent in connection with Krka’s application to trading on the WSE.
About Krka
Krka Group is one of the world’s leading generic pharmaceutical companies. It is headquartered in Novo mesto, Slovenia, and has more than 50 years experience in the industry. In 2011, Krka posted €1,076 million in revenues and €163 million in net income.
Krka Group is engaged in the development, production, sale and marketing of branded prescription pharmaceuticals supplemented by non prescription pharmaceuticals (mostly self-medication and cosmetics), animal health products and health & tourism services. The group employs approximately 9,000 people and has production facilities in Slovenia, Poland, Croatia, Germany and the Russian Federation.
The group sells its products globally to over 70 countries with a leading market share position in key markets and strong brand recognition. The largest sales region is Central Europe followed by Eastern Europe, Western Europe & Overseas Markets, South-East Europe and Slovenia.
The market capitalisation of Krka on Ljubljana Stock Exchange as of 10 April 2012 amounted to €1.715 billion.
IMPORTANT INFORMATION
THESE MATERIALS ARE NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OR IN OTHER COUNTRIES WHERE THE PUBLIC DISSEMINATION OF THE INFORMATION CONTAINED HEREIN MAY BE RESTRICTED OR PROHIBITED BY LAW.
These materials are for promotional purposes only, and under no circumstances shall constitute the basis for a decision to invest in the shares of Krka, d. d., Novo mesto (the “Company”). The information memorandum (the “Information Memorandum”) prepared in connection with seeking the admission and introduction of the Company’s securities to trading on the Warsaw Stock Exchange (“WSE”) (the “Admission”) on the basis of Art. 39, par 1, in connection with Art. 7 par. 4 point 8) of the Polish Act on Public Offering, Conditions Governing the Introduction of Financial Instruments to Organised Trading, and Public Companies of 29 July 2005 and the Polish Regulation of the Minister of Finance of 6 July 2007 on the Detailed Conditions to be Met by an Information Memorandum Referred to in Art. 39.1 and Art. 42.1 of the Polish Act on Public Offering, Conditions Governing the Introduction of Financial Instruments to Organised Trading, and Public Companies, together with any other statutory required disclosure, is the sole legally binding document containing information on the Admission. For the purposes of the Admission, the Company made the Information Memorandum available on the Company’s website (http://www.krka.biz/en/) on 2 April 2012.
These materials are not an offer of securities for sale in the United States. Securities may not be offered or sold in the United States absent registration or an exemption from registration under the United States Securities Act of 1933, as amended (the “Securities Act”). The securities to which these materials relate have not been and will not be registered under the Securities Act and there will be no public offering of the securities in the United States.
